Market Cap 19.48B
Revenue (ttm) 363.71M
Net Income (ttm) -913.77M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -251.24%
Debt to Equity Ratio 11.14
Volume 3,504,900
Avg Vol 3,196,624
Day's Range N/A - N/A
Shares Out 189.71M
Stochastic %K 100%
Beta 0.80
Analysts Strong Sell
Price Target $110.59

Company Profile

Insmed Incorporated develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. The company offers ARIKAYCE for the treatment of refractory nontuberculous mycobacterial lung infections, as well as is in phase 3 clinical trial for the treatment of mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It also devlops brensocatib, an oral reversible inhibitor of...

Industry: Biotechnology
Sector: Healthcare
Phone: 908 977 9900
Address:
700 US Highway 202/206, Bridgewater, United States
pianoman439
pianoman439 Jun. 24 at 12:17 PM
$INSM when Lewis took over as CEO, enterprise value was zero. Stock price fell to under $3.00. He resurrected the company by unlocking Arikayce value and navigating FDA road blocks. But the piece de resistance was licensing Brensocatib from AZN for 30 million dollars. Now Insmed is worth 20 billion largely due to this drug! TPIP is icing on the cake, but don’t forget the fourth pillar. Succeeding at 1-3 gives me great confidence in 4. Insmed is on its way to being #1 biotech in the 21st Century in my estimation.
0 · Reply
Dark_Horse_Investments
Dark_Horse_Investments Jun. 23 at 7:32 PM
$INSM Hi what do analysts estimate annual peak revenue for this company? Cognizant, multi drug and timing complicates analysis. This is nearly a ~$20 billion cap whereas $VRNA is ~$8.2 billion. This is interesting...
3 · Reply
iwtd
iwtd Jun. 23 at 2:40 PM
$INSM - Insmed Incorporated. Looking at the technical chart below this stock can rise 20% from the current price in weeks/months. I don't discuss the fundamentals here as that would make the post too long.
0 · Reply
JoeB07
JoeB07 Jun. 22 at 1:47 AM
$INSM This company will not be sold, it is unaffordable. Brenso is being compared to Humira--the largest selling drug in history. I say again, Insmed is about to launch a drug that is bgeing compared to the largest selling drug in history. Will Lewis is 3/3 on Phase 2B/3 trials. He picks winners better than any CEO in the industry. This company will destroy it as a stand-alone. Easy 5x your money in 3-5 years... and one of the biggest pharmas in the industry in 10 yrs. The biggest holders know this, which is why they keep buying every available share. Which is why Will recalled the debt--to increase float shares for the biggest holders. Shorts are f/ed. They added on RFK/Trump nonsense and then added more prior to TPIP. They are absolutely f'ed. Shorts are looking at August and now it's apparant that Insmed owners are not going to sell out. They are going to drive the price higher. The Brenso approval is going to result in another 40-50% move. Insmed is going parabolic. It's inevitable
1 · Reply
stu
stu Jun. 21 at 5:28 PM
$INSM A take from Wells Fargo on BO candidates with potential suitors & their probability ranking (low-medium-high).
0 · Reply
GolfProLife
GolfProLife Jun. 19 at 12:25 AM
$INSM looking for some consolidation and continued pull back the price discovery to find the new range bound stock price. Also keeping an eye on the $120 Strike Call Option Chain expiring 08/15. Their is an unusual amount of open contracts their similar to the $80 strike option chain that expires this Friday. Not as much open contracts but much more so then the usual where someone might know something again anticipating the FDA approval of Brensocatib. Waiting a little bit more to see where price discovery takes us before I buy back in. The CEO said they anticipate an August 12th release date for Brensocatib to hit the market so I’m very curious if the market has already priced in the FDA approval and could this be a sell the news event. I don’t think it will be, but I also don’t expect another almost 40 percent move like we just saw with the positive phase two data from the TPIP trails. IMO the market is pricing in the FDA approval somewhat, and the move will be smaller.
3 · Reply
Night_Owl_Biotech
Night_Owl_Biotech Jun. 17 at 7:18 PM
BPMC today filed their 14D9 today that includes, among other data points, a review of revenue multiples paid in transactions considered peers to BPMC for valuation purposes. BPMC engaged Centerview & Jeffries who noted the following Year 4 multiples paid in recent M&A transactions. SWTX was acquired for 2.6X its FY2028 (or year 4) revenue projection which appears on the low end if these are appropriate peers for SWTX @patten1962 Other commercial-stage bios rumored to be M&A candidates, and hence may find these interesting, include; $MDGL $VRNA $INSM $LEGN $TARS This is not investment advice. We've never been able to ID M&A candidates.
1 · Reply
JoeB07
JoeB07 Jun. 17 at 12:22 PM
$INSM $GS 100 -> 112
1 · Reply
JoeB07
JoeB07 Jun. 17 at 2:26 AM
$INSM is now the $PLTR of bio/healthcare. The next $VRTX, but bigger. Like Humira and Keytruda combined. Brenso! Unbelievable potential. Going to ride the upper BBs through the analyst targets and beyond. Have fun. Get rich.!
0 · Reply
EatingCatPoop
EatingCatPoop Jun. 16 at 9:08 PM
$INSM who keeps buying this here when $LQDA just got approved for an arguably better drug for the same market and is valued at barely $1B??
1 · Reply
Latest News on INSM
Is Insmed Stock Overvalued After The 45% Jump?

Jun 16, 2025, 5:05 AM EDT - 8 days ago

Is Insmed Stock Overvalued After The 45% Jump?


Insmed: Company Presses On With Further POC PAH Treatment Data

Jun 10, 2025, 4:30 PM EDT - 13 days ago

Insmed: Company Presses On With Further POC PAH Treatment Data


Insmed's blood pressure drug meets main goal in mid-stage trial

Jun 10, 2025, 7:25 AM EDT - 14 days ago

Insmed's blood pressure drug meets main goal in mid-stage trial


Insmed Incorporated (INSM) Q1 2025 Earnings Call Transcript

May 8, 2025, 2:55 PM EDT - 6 weeks ago

Insmed Incorporated (INSM) Q1 2025 Earnings Call Transcript


Insmed: Poised For Transformation Beyond ARIKAYCE

Apr 25, 2025, 11:58 AM EDT - 2 months ago

Insmed: Poised For Transformation Beyond ARIKAYCE


Insmed Incorporated (INSM) Q4 2024 Earnings Call Transcript

Feb 20, 2025, 12:50 PM EST - 4 months ago

Insmed Incorporated (INSM) Q4 2024 Earnings Call Transcript


Insmed To Present at March 2025 Investor Conferences

Feb 11, 2025, 8:00 AM EST - 4 months ago

Insmed To Present at March 2025 Investor Conferences


Insmed To Present at December 2024 Investor Conferences

Dec 2, 2024, 8:00 AM EST - 7 months ago

Insmed To Present at December 2024 Investor Conferences


Insmed To Present at November 2024 Investor Conferences

Nov 6, 2024, 8:00 AM EST - 8 months ago

Insmed To Present at November 2024 Investor Conferences


Insmed Incorporated (INSM) Q3 2024 Earnings Call Transcript

Oct 31, 2024, 2:31 PM EDT - 8 months ago

Insmed Incorporated (INSM) Q3 2024 Earnings Call Transcript


Insmed Incorporated (INSM) Q2 2024 Earnings Call Transcript

Aug 9, 2024, 4:11 PM EDT - 11 months ago

Insmed Incorporated (INSM) Q2 2024 Earnings Call Transcript


Insmed (INSM) CEO on the Company's Current Product Pipeline

Jun 4, 2024, 4:38 PM EDT - 1 year ago

Insmed (INSM) CEO on the Company's Current Product Pipeline


pianoman439
pianoman439 Jun. 24 at 12:17 PM
$INSM when Lewis took over as CEO, enterprise value was zero. Stock price fell to under $3.00. He resurrected the company by unlocking Arikayce value and navigating FDA road blocks. But the piece de resistance was licensing Brensocatib from AZN for 30 million dollars. Now Insmed is worth 20 billion largely due to this drug! TPIP is icing on the cake, but don’t forget the fourth pillar. Succeeding at 1-3 gives me great confidence in 4. Insmed is on its way to being #1 biotech in the 21st Century in my estimation.
0 · Reply
Dark_Horse_Investments
Dark_Horse_Investments Jun. 23 at 7:32 PM
$INSM Hi what do analysts estimate annual peak revenue for this company? Cognizant, multi drug and timing complicates analysis. This is nearly a ~$20 billion cap whereas $VRNA is ~$8.2 billion. This is interesting...
3 · Reply
iwtd
iwtd Jun. 23 at 2:40 PM
$INSM - Insmed Incorporated. Looking at the technical chart below this stock can rise 20% from the current price in weeks/months. I don't discuss the fundamentals here as that would make the post too long.
0 · Reply
JoeB07
JoeB07 Jun. 22 at 1:47 AM
$INSM This company will not be sold, it is unaffordable. Brenso is being compared to Humira--the largest selling drug in history. I say again, Insmed is about to launch a drug that is bgeing compared to the largest selling drug in history. Will Lewis is 3/3 on Phase 2B/3 trials. He picks winners better than any CEO in the industry. This company will destroy it as a stand-alone. Easy 5x your money in 3-5 years... and one of the biggest pharmas in the industry in 10 yrs. The biggest holders know this, which is why they keep buying every available share. Which is why Will recalled the debt--to increase float shares for the biggest holders. Shorts are f/ed. They added on RFK/Trump nonsense and then added more prior to TPIP. They are absolutely f'ed. Shorts are looking at August and now it's apparant that Insmed owners are not going to sell out. They are going to drive the price higher. The Brenso approval is going to result in another 40-50% move. Insmed is going parabolic. It's inevitable
1 · Reply
stu
stu Jun. 21 at 5:28 PM
$INSM A take from Wells Fargo on BO candidates with potential suitors & their probability ranking (low-medium-high).
0 · Reply
GolfProLife
GolfProLife Jun. 19 at 12:25 AM
$INSM looking for some consolidation and continued pull back the price discovery to find the new range bound stock price. Also keeping an eye on the $120 Strike Call Option Chain expiring 08/15. Their is an unusual amount of open contracts their similar to the $80 strike option chain that expires this Friday. Not as much open contracts but much more so then the usual where someone might know something again anticipating the FDA approval of Brensocatib. Waiting a little bit more to see where price discovery takes us before I buy back in. The CEO said they anticipate an August 12th release date for Brensocatib to hit the market so I’m very curious if the market has already priced in the FDA approval and could this be a sell the news event. I don’t think it will be, but I also don’t expect another almost 40 percent move like we just saw with the positive phase two data from the TPIP trails. IMO the market is pricing in the FDA approval somewhat, and the move will be smaller.
3 · Reply
Night_Owl_Biotech
Night_Owl_Biotech Jun. 17 at 7:18 PM
BPMC today filed their 14D9 today that includes, among other data points, a review of revenue multiples paid in transactions considered peers to BPMC for valuation purposes. BPMC engaged Centerview & Jeffries who noted the following Year 4 multiples paid in recent M&A transactions. SWTX was acquired for 2.6X its FY2028 (or year 4) revenue projection which appears on the low end if these are appropriate peers for SWTX @patten1962 Other commercial-stage bios rumored to be M&A candidates, and hence may find these interesting, include; $MDGL $VRNA $INSM $LEGN $TARS This is not investment advice. We've never been able to ID M&A candidates.
1 · Reply
JoeB07
JoeB07 Jun. 17 at 12:22 PM
$INSM $GS 100 -> 112
1 · Reply
JoeB07
JoeB07 Jun. 17 at 2:26 AM
$INSM is now the $PLTR of bio/healthcare. The next $VRTX, but bigger. Like Humira and Keytruda combined. Brenso! Unbelievable potential. Going to ride the upper BBs through the analyst targets and beyond. Have fun. Get rich.!
0 · Reply
EatingCatPoop
EatingCatPoop Jun. 16 at 9:08 PM
$INSM who keeps buying this here when $LQDA just got approved for an arguably better drug for the same market and is valued at barely $1B??
1 · Reply
Holmes700R
Holmes700R Jun. 16 at 6:51 PM
$INSM crazy high valuation… needs a drop
1 · Reply
D_stocker
D_stocker Jun. 16 at 2:41 PM
$INSM I see they were able to sell shares at $91.68 instead of $96. I still don’t think that is a low enough number. Jim
2 · Reply
pianoman439
pianoman439 Jun. 13 at 11:43 PM
$INSM anyone gonna peg 💯 for the last trade AH?
0 · Reply
Bobray1
Bobray1 Jun. 13 at 7:32 PM
$INSM all u clowns predicting 60 to 80 dollars should move to another stock.
2 · Reply
Pegy
Pegy Jun. 13 at 4:52 PM
$INSM Yes, INSM can certainly dip below $95, and here’s why it’s a plausible scenario: ⸻ 🔹 1. Dilution & Offering Risk • The recent $750M offering at $96 adds ~4.5% more float, plus a greenshoe that could push dilution higher—this creates downward pressure . • Continued share selling by insiders and overhang could keep sentiment cautious . ⸻ 🔹 2. Technical Levels & Volatility • Daily support sits around $90.9, with next floors at $76.3 and $72.7 if initial levels fail . • Intraday expected range today spans $92.7–$101.0, meaning a dip under $95 is well within normal volatility . ⸻ 🔹 3. Mixed Technical Signals • TradingView shows a mix: short‑term oscillator is Sell, but moving averages lean Strong Buy—indicating a tug-of-war . • ChartMill sees neutral‑short trend with a strong support zone around $76.98 .
1 · Reply
caemeroon
caemeroon Jun. 13 at 4:09 PM
$INSM still confused on the price action vs volume because 7.8M shares are supposed to be hitting the market by EOD. Offering was announced yesterday after midnight. Volume yesterday was a little over 7M and today it is a little over 2M. I just don’t think these shares have hit yet or they aren’t being sold in very large blocks or something is amiss. Help me understand this one?
2 · Reply
pianoman439
pianoman439 Jun. 13 at 1:38 PM
$INSM following an identical pattern to Brensocatib data release a year ago.
1 · Reply
caemeroon
caemeroon Jun. 13 at 1:34 PM
$INSM at least this morning, so far, I stand corrected.
1 · Reply
Survivingcovid
Survivingcovid Jun. 13 at 11:59 AM
$INSM perfect time for the company to unload those shares today. PT $75 by next week.
0 · Reply
JoeB07
JoeB07 Jun. 13 at 11:20 AM
$INSM going to surge at the open. Have fun.
1 · Reply
Holmes700R
Holmes700R Jun. 13 at 9:52 AM
$INSM wouldn’t be suprised to see this get shorted down to $60 again over time… people buying these additional shares will be shorting them immediately for sure.
0 · Reply
caemeroon
caemeroon Jun. 13 at 1:40 AM
$INSM bid is at 91 after hours (it’s after hours though right?) well the ask is $95. Tomorrow the bottom falls out I think. 7.8M share offering “to be completed by Friday” per the press release. I could be wrong but I don’t know how it holds $90-$92 region
0 · Reply